Buprenorphine And Naloxone
Product Images NDC 67296-2096

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Buprenorphine And Naloxone (NDC 67296-2096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn12mg.jpg (Ctn12mg)

Packaging label for Buprenorphine and Naloxone Sublingual Film 12 mg/3 mg manufactured for Ingenus Pharmaceuticals, LLC. The box contains 30 pouches, each with one sublingual film. The label includes dosage instructions, safety warnings, and storage conditions. The NDC shown is 50742-365-30 and the label indicates prescription-only status.*

FDA Label Image

Ctn8mg.jpg (Ctn8mg)

Packaging label for Buprenorphine and Naloxone Sublingual Film 8 mg/2 mg by RedPharm Drug. The label shows a carton containing 30 pouches, each with one sublingual film. It includes usage warnings, administration instructions, storage conditions, and barcode information. Manufactured for Ingenus Pharmaceuticals, Orlando, FL.*

FDA Label Image

Figure3.jpg (Figue3)

An anatomical line drawing showing a frontal view of an open mouth with visible teeth, tongue, and throat. The illustration focuses on the oral cavity without additional text or labels.*

FDA Label Image

Figure1.jpg (Figure1)

An instructional illustration showing hands holding and peeling apart a strip or patch from a backing. The two-panel image demonstrates the removal process by pulling the edges away from each other. This likely indicates how to open or activate the product packaging for Buprenorphine and Naloxone.*

FDA Label Image

Figure2.jpg (Figure2)

An instructional illustration showing hands opening a foil pouch by pulling apart the tear notches on each side. The second part shows peeling back the foil edge to open the pouch fully.*

FDA Label Image

Figure4.jpg (Figure4)

An instructional diagram in two panels illustrating the placement of a sublingual or buccal tablet inside the mouth. The first panel shows a hand placing the tablet inside the lower cheek area, while the second panel shows the tablet positioned inside the open mouth, resting against the inner cheek.*

FDA Label Image

Structurebuprenorpine.jpg (Structurebuprenorpine)

Chemical structure of buprenorphine hydrochloride, showing its molecular configuration including hydroxyl, methoxy, and cyclopropyl groups.*

FDA Label Image

Structurenaloxone.jpg (Structurenaloxone)

Chemical structure of Buprenorphine, the active ingredient in Buprenorphine and Naloxone by RedPharm Drug. The diagram shows the molecular arrangement including hydroxyl, ether, amine groups, and indication of hydrochloride dihydrate form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.